pioglitazone has been researched along with Atrial Fibrillation in 12 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Atrial Fibrillation: Abnormal cardiac rhythm that is characterized by rapid, uncoordinated firing of electrical impulses in the upper chambers of the heart (HEART ATRIA). In such case, blood cannot be effectively pumped into the lower chambers of the heart (HEART VENTRICLES). It is caused by abnormal impulse generation.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects." | 9.19 | Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 7.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 7.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 7.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not." | 6.76 | Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 5.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| "This study aimed to explore the effects of pioglitazone treatment on progression from persistent atrial fibrillation (AF) to permanent atrial fibrillation in diabetes mellitus (DM) patients and to investigate the possible mechanisms involved in those effects." | 5.19 | Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients. ( Liu, B; Wang, G; Wang, J, 2014) |
| " Pioglitazone (an oral hypoglycemic agent of the thiazolidinedione drug class) was shown in the IRIS trial to reduce the risk of recurrent stroke in patients with impaired glucose tolerance who had not developed type 2 diabetes mellitus." | 4.98 | Updates in Stroke Treatment. ( Mac Grory, B; Yaghi, S, 2018) |
| " We sought to investigate the potential effects of pioglitazone, a PPAR-γ activator, on atrial remodeling and atrial fibrillation (AF) inducibility in diabetic rabbits." | 3.85 | Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits. ( Cheng, L; Fu, H; Korantzopoulos, P; Li, G; Li, J; Liu, C; Liu, R; Liu, T; Tse, G; Wang, X, 2017) |
| "The purpose of this study was to test the hypothesis that atrial fibrosis and enhanced vulnerability to AF evoked by pressure overload can be attenuated by pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, via suppression of inflammatory profibrotic signals." | 3.77 | Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. ( Hara, M; Kume, O; Nagano-Torigoe, Y; Nakagawa, M; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O; Yoshimatsu, H; Yufu, K, 2011) |
| "Rabbits subjected to ventricular tachypacing at 380 to 400 bpm for 4 weeks in the absence and presence of treatment with pioglitazone, candesartan, and combined pioglitazone and candesartan were assessed by electrophysiologic study, atrial fibrosis measurements, and cytokine expression analyses." | 3.74 | Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. ( Harata, S; Inden, Y; Kitamura, K; Murohara, T; Nattel, S; Shimano, M; Tsuji, Y; Uchikawa, T, 2008) |
| "All patients had a history of type 2 diabetes mellitus (T2DM) and were divided based on whether they received pioglitazone before ablation or not." | 2.76 | Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. ( Gu, J; Jiang, W; Liu, X; Shi, H; Tan, H; Wang, X; Wang, Y; Zhou, L, 2011) |
| "Treatment with pioglitazone, a peroxisome proliferator-activated receptor-γ agonist, resulted in attenuation of pressure overload-induced LA fibrosis." | 2.48 | Novel strategy to prevent atrial fibrosis and fibrillation. ( Fukunaga, N; Hara, M; Kume, O; Saikawa, T; Takahashi, N; Teshima, Y; Wakisaka, O, 2012) |
| "Pioglitazone treatment significantly increased phosphorylated (p-) Akt but significantly reduced p-ERK1/2 and p-JNK." | 1.38 | PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. ( Aonuma, K; Hirayama, A; Igarashi, M; Ito, Y; Murakoshi, N; Seo, Y; Tada, H; Xu, D, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 9 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Liu, C | 2 |
| Liu, R | 1 |
| Fu, H | 1 |
| Li, J | 1 |
| Wang, X | 2 |
| Cheng, L | 1 |
| Korantzopoulos, P | 2 |
| Tse, G | 1 |
| Li, G | 3 |
| Liu, T | 3 |
| Mac Grory, B | 1 |
| Yaghi, S | 1 |
| Liu, B | 1 |
| Wang, J | 1 |
| Wang, G | 1 |
| Kume, O | 2 |
| Takahashi, N | 2 |
| Wakisaka, O | 2 |
| Nagano-Torigoe, Y | 1 |
| Teshima, Y | 2 |
| Nakagawa, M | 1 |
| Yufu, K | 1 |
| Hara, M | 2 |
| Saikawa, T | 2 |
| Yoshimatsu, H | 1 |
| Duffy, HS | 1 |
| Gu, J | 2 |
| Liu, X | 1 |
| Shi, H | 1 |
| Tan, H | 1 |
| Zhou, L | 1 |
| Jiang, W | 1 |
| Wang, Y | 1 |
| Xu, D | 1 |
| Murakoshi, N | 1 |
| Igarashi, M | 1 |
| Hirayama, A | 1 |
| Ito, Y | 1 |
| Seo, Y | 1 |
| Tada, H | 1 |
| Aonuma, K | 1 |
| Fukunaga, N | 1 |
| Shimano, M | 1 |
| Tsuji, Y | 1 |
| Inden, Y | 1 |
| Kitamura, K | 1 |
| Uchikawa, T | 1 |
| Harata, S | 1 |
| Nattel, S | 1 |
| Murohara, T | 1 |
| Wilson, LD | 1 |
| Tsai, CT | 1 |
| Goudevenos, JA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Combination Therapy With Dapagliflozin Plus Low Dose Pioglitazone on Hospitalization Rate in Patients With Heart Failure and Preserved Left Ventricular Ejection Fraction[NCT03794518] | Phase 3 | 648 participants (Anticipated) | Interventional | 2019-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for pioglitazone and Atrial Fibrillation
| Article | Year |
|---|---|
Updates in Stroke Treatment.
Topics: Acute Disease; Atrial Fibrillation; Brain Ischemia; Glucose Intolerance; Humans; Hypoglycemic Agents | 2018 |
Novel strategy to prevent atrial fibrosis and fibrillation.
Topics: Animals; Antioxidants; Atrial Fibrillation; Chemokine CCL2; Disease Models, Animal; Endothelial Cell | 2012 |
2 trials available for pioglitazone and Atrial Fibrillation
| Article | Year |
|---|---|
Beneficial effects of pioglitazone on retardation of persistent atrial fibrillation progression in diabetes mellitus patients.
Topics: Aged; Angiotensin II; Atrial Fibrillation; Diabetes Complications; Disease Progression; Double-Blind | 2014 |
Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus.
Topics: Aged; Atrial Fibrillation; Catheter Ablation; Diabetes Mellitus, Type 2; Diabetic Cardiomyopathies; | 2011 |
8 other studies available for pioglitazone and Atrial Fibrillation
| Article | Year |
|---|---|
Pioglitazone attenuates atrial remodeling and vulnerability to atrial fibrillation in alloxan-induced diabetic rabbits.
Topics: Action Potentials; Alloxan; Animals; Atrial Fibrillation; Atrial Remodeling; Diabetes Mellitus, Expe | 2017 |
Pioglitazone may offer therapeutic advantages in diabetes-related atrial fibrillation.
Topics: Atrial Fibrillation; Diabetes Mellitus; Humans; Hypoglycemic Agents; Pioglitazone; Thiazolidinedione | 2013 |
Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats.
Topics: Administration, Oral; Animals; Atrial Fibrillation; Blotting, Western; Disease Models, Animal; Echoc | 2011 |
Inflammatory responses in the atria: should they stay or should they go?
Topics: Animals; Atrial Fibrillation; Disease Models, Animal; Fibrosis; Heart Atria; Inflammation; Inflammat | 2011 |
PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model.
Topics: Aging; Animals; Antioxidants; Apoptosis; Atrial Fibrillation; Cardiotonic Agents; Disease Models, An | 2012 |
Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure.
Topics: Analysis of Variance; Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimi | 2008 |
Heart failure-related atrial fibrillation: a new model for a new prevention strategy?
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Benzimidazoles; Biphenyl Comp | 2008 |
Role of pioglitazone treatment on atrial remodeling and atrial fibrillation (AF)promotion in an experimental model of congestive heart failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atrial Fibrillation; Disease Models, Animal; Heart | 2008 |